Sequella has agreed with a Russian venture fund to develop a treatment for tuberculosis in the Russian Federation and neighboring countries in a deal that could be worth as much as $50 million to the Rockville biotechnology company, executives said today.
It is the first licensing deal for Sequella's drug candidate SQ109 and marks the first time that Sequella will work in Russia, said Alan S. Klein, executive vice president, corporate development. That market is significant due to the number of TB cases there, he said.
Russia is considered one of the world's "high burden" TB countries, with more than 150,000 cases of active TB reported each year, according to the World Health Organization. The Russian market for anti-tubercular drugs is more than $150 million annually, according to privately held Sequella.
To read the full, original article click on this link: From Russia with millions
Author: Kevin James Shay
